Evidence map›Paper›PMID 35201913›Full record

ArticleInnate immunity2022

A novel antimicrobial peptide derived from human BPIFA1 protein protects against

Nan Hu, Xi-Ming Mo, Shi-Na Xu, Hao-Neng Tang, Ying-Hui Zhou, Long Li, Hou-De Zhou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Innate immunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Nan HuNational Clinical Research Center for Metabolic Diseases, Hunan Provincial Key Laboratory for Metabolic Bone Diseases, and Department of Metabolism and Endocrinology, 70566The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China.
Xi-Ming MoDepartment of clinical laboratory medicine, 547499The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China.
Shi-Na XuNational Clinical Research Center for Metabolic Diseases, Hunan Provincial Key Laboratory for Metabolic Bone Diseases, and Department of Metabolism and Endocrinology, 70566The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China.
Hao-Neng TangNational Clinical Research Center for Metabolic Diseases, Hunan Provincial Key Laboratory for Metabolic Bone Diseases, and Department of Metabolism and Endocrinology, 70566The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China.
Ying-Hui ZhouNational Clinical Research Center for Metabolic Diseases, Hunan Provincial Key Laboratory for Metabolic Bone Diseases, and Department of Metabolism and Endocrinology, 70566The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China.
Long LiNational Clinical Research Center for Metabolic Diseases, Hunan Provincial Key Laboratory for Metabolic Bone Diseases, and Department of Metabolism and Endocrinology, 70566The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China.
Hou-De ZhouNational Clinical Research Center for Metabolic Diseases, Hunan Provincial Key Laboratory for Metabolic Bone Diseases, and Department of Metabolism and Endocrinology, 70566The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China.ORCID 0000-0001-9131-4141
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bactericidal/permeability-increasing fold containing family A, member 1 (BPIFA1) is an innate immunity defense protein. Our previous studies proved its antibacterial and antiviral effects, but its role in fungi remains unknown. The study aimed to identify antifungal peptides (AFP) derived from BPIFA1, and three antimicrobial peptides (AMP1-3) were designed. The antifungal effects were proved by growth inhibition assay. AMP3 activity was confirmed by germ tube growth experiment and XTT assay. Its effects on cell wall and membrane of

Indexed as

Antifungal AgentsCandida albicansalpha-FetoproteinsAntimicrobial PeptidesBiofilmsGlycoproteinsHumansMicrobial Sensitivity TestsPhosphoproteinsalpha-FetoproteinsAntifungal AgentsAntimicrobial PeptidesBPIFA1 protein, humanGlycoproteinsPhosphoproteinsanti-fungal peptidebiofilmBPIFA1candida albicansinnate immunity

Identifiers

PMID35201913
PMCPMC9058375
OpenAlexW4213434628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.